Does a moderate dose fish oil intervention improve outcomes in older adults recovering from hip fracture?
A Trial Assessing omega-3 fatty acids (N-3) as Treatment for Injury-induced Cachexia
Dr Michelle Miller
150 participants
Aug 1, 2010
Interventional
Conditions
Summary
The anti-inflammatory properties of fish oil are well documented. Hip fracture is common and patients suffer significant unintentional weight and muscle loss leading to poor outcomes. An inflammatory response to the injury is a plausible mechanism for the lack of response observed in these patients when provided with best practice nutrition. This study aims to reduce the weight loss suffered by hip fracture patients by prescribing an intervention of individualised nutrition support and fish oil.
Eligibility
Inclusion Criteria7
- Aged >65 years
- PFF confirmed by radiology report
- Undergone surgery for fixation of hip fracture
- Reside within existing local service boundaries
- Community dwelling
- Preliminary evidence of cachexia (CRP =6mg/L)
- At risk of significant weight loss (SNAQ score =14/20)
Exclusion Criteria12
- Severe cognitive impairment (MMSE <18/30)
- PFF not fall-related, is pathological or is peri-prosthetic
- Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks
- Ingestion of =2g total omega-3 daily as per fish FFQ
- Seafood allergy
- Life expectancy <12 weeks
- Inability to communicate effectively due to blindness, deafness or lack of a translator
- Inability to provide informed consent
- Diagnosed with one of the following haemorrhagic stroke risk factors (Unstable hypertension, Atrial fibrillation, Inherited disorders such as polycystic kidney disease, Ehlers-Danlos syndrome type IV, neurofibromatosis type I, Marfan syndrome, moyamoya disease)
- Diagnosed with a bleeding disorders such as the following (von Willebrand disease or Haemophilia
- Receiving treatment doses of any antithrombotic agent
- Those on dual anti-platelet function drugs or any anti-platelet drugs with exception to low dose aspirin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
12-week well integrated, coordinated, individualized nutrition therapy plan consistent with estimated nutritional requirements and nutritional rehabilitation goals combined with moderate dose liquid fish oil intervention (20ml/d; 3g eicosapentanoic acid (EPA) and 2g docosahexanoic acid (DHA)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000241235